유전체 시퀀싱 시장 - 세계 및 지역별 분석 : 제품별, 기술별, 용도별, 유형별, 최종사용자별, 지역별 - 분석 및 예측(2024-2033년)

Global Genome Sequencing Market Industry Overview

The global genome sequencing market was valued at $7.56 billion in 2023 and is expected to reach $30.23 billion by 2033, growing at a CAGR of 15.18% between 2024 and 2033. Genome sequencing is a method that allows researchers to decode the entire genetic information of an organism. This technique reveals the full sequence of DNA in an organism, helping to identify genetic variations and their implications for health and disease. The growth of the genome sequencing market is driven by several factors, such as decreasing the cost of genome sequencing, enabling high usage of genome sequencing/testing, rising prenatal and new-born screening programs facilitating the demand for next-generation sequencing, and expanding applications of long-read sequencing. Additionally, government investments and initiatives in genome sequencing projects have further facilitated market expansion and accessibility to consumers worldwide.

Market Introduction

The genome sequencing market is experiencing rapid growth, driven by increasing demand among researchers for tools capable of generating richer, more comprehensive data across various omics disciplines such as genomic, transcriptomic, and epigenetics. Recent advances in genomic technologies have sparked new therapies and diagnostics, but full integration into clinical practice is hindered by challenges such as long analysis times. Innovations, such as Illumina's long-read sequencing, are improving data handling and expanding applications in fields such as disease surveillance and environmental monitoring.

With the growing accessibility and affordability of genome sequencing, its adoption is increasing across various industries, notably in personalized medicine and genetic research. This trend underscores the vital role of genome sequencing in exploring and addressing genetic diseases and conditions. As this technology continues to advance, the genome sequencing market is poised for considerable expansion and innovation, significantly impacting the healthcare sector.

Industrial Impact

The genome sequencing market is reshaping healthcare by enabling personalized medicine approaches. By leveraging detailed genetic profiles, treatments can be tailored to individual patients, enhancing both outcomes and the efficiency of medical care. This technology plays a critical role in diagnosing genetic disorders, understanding disease pathways, and developing targeted treatments, significantly improving patient outcomes.

Market Segmentation:

Segmentation 1: by Product

• Kits
• Instruments
• Software

Kits Segment to Dominate the Genome Sequencing Market (by Product)

The kits segment is poised to dominate the genome sequencing market by product, as these kits deliver all-in-one solutions for researchers working on genomic studies. These kits streamline the processes of isolating genomic samples, preparing sequencing libraries, and executing sequencing reactions.

Segmentation 2: by Technology

• First-Generation Sequencing
• Next-Generation Sequencing
• Third-Generation Sequencing
• Fourth-Generation Sequencing

Next-Generation Sequencing to Dominate the Genome Sequencing Market (by Technology)

The next-generation sequencing segment is positioned to dominate the genome sequencing market by technology, as it significantly improves the speed, precision, and cost-efficiency of gene sequencing, leading to remarkable advancements in diagnostics and treatments.

Segmentation 3: by Type

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing
• RNA Sequencing

Targeted Sequencing to Dominate the Genome Sequencing Market (by Type)

The targeted sequencing segment is positioned to dominate the genome sequencing market by type, as it offers precise insights into specific areas of the genome, making it a crucial tool in oncology, genetic disorders, immunology, and infectious diseases. By focusing on select genes, coding regions, or chromosome segments, this approach provides high accuracy and efficiency.

Segmentation 4: by Application

• Research Applications
• Clinical Diagnostics
• Biopharma R&D
• Food and Agriculture
• Forensics

Research Applications to Dominate the Genome Sequencing Market (by Application)

The research applications segment is positioned to dominate the genome sequencing market by application, as it is an essential tool in biological and medical research, allowing scientists to gain in-depth insights into genetic structures, functions, and variations.

Segmentation 5: by End User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Population Sequencing Organizations
• Research and Academic Institutes
• Others

Research and Academic Institutes to Dominate the Genome Sequencing Market (by End User)

The research and academic institutes segment is positioned to dominate the genome sequencing market by end user due to the widespread availability of NGS instruments and consumables designed primarily for academic and research institutions.

Segmentation 6: by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • Spain
  • Italy
  • France
  • Rest-of-Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest-of-Latin America
• Rest-of-the-World

The North America region is positioned to hold a significant share of the global market for several compelling reasons, including a robust ecosystem of innovative biotechnology and life sciences companies. The Asia-Pacific region has experienced rapid market growth due to rising healthcare investments and advancements in genomic technologies. Major countries such as China, Japan, and Australia are in charge of applying genome sequencing in healthcare and agriculture. With its substantial population and evolving healthcare infrastructure, the Asia-Pacific market is positioned for significant expansion.

Recent Developments in the Genome Sequencing Market

• In February 2024, Volta Labs, a genomics applications company, and Element Biosciences, Inc., a developer of pioneering technologies, collaborated to optimize sequencing throughput with the launch of Volta's Callisto Sample Prep System for Element's AVITI platform.
• In February 2024, Twist Bioscience Corporation and Element Biosciences, Inc. collaborated to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element's AVITI System.
• In January 2024, Pacific Biosciences of California, Inc. unveiled PanDNA, a versatile Nanobind DNA extraction kit. This new product broadens the spectrum of sample types compatible with long-read sequencing, encompassing cells, bacteria, blood, tissue, plant nuclei, and insects.
• In February 2024, Ultima Genomics, Inc. launched the UG 100 Sequencer to drive forward affordable genomic sequencing.

Demand - Drivers, Challenges, and Opportunities

Market Drivers:

Rising Prenatal and New-Born Screening Programs Facilitating the Demand for Next-Generation Sequencing: Integrating next-generation sequencing (NGS) into new-born screening programs is boosting the global genome sequencing market. NGS allows early detection of multiple genetic disorders in a single test, enabling timely interventions and reducing infant mortality. As NGS technology advances and becomes more cost-effective, it consolidates multiple tests into one and supports personalized healthcare, driving substantial market growth.

Market Challenges:

Genomic Data Disparity in Developing Countries: A major challenge in the genome sequencing market is the lack of genomic data from African populations, as highlighted in a 2023 Nature paper. Most genetic data is from European ancestries, leading to less effective diagnostics for Africans. African genomes are highly diverse but underrepresented, causing potential misdiagnoses. Limited infrastructure and workforce further hinder precision medicine in Africa. Increased investment in genomic research and infrastructure is needed to address this gap and ensure equitable market growth.

Market Opportunities:

Emergence of Portable Genome Sequencing Enabling Bedside Testing: Advancements in point-of-care testing (POCT) technologies are boosting the global genome sequencing market with portable devices such as Oxford Nanopore's MinION. These devices enable immediate, onsite testing, which is crucial in emergency healthcare settings. They proved effective during the Ebola outbreak by identifying viral pathogens quickly. Portable genome sequencing also aids in rapid cancer diagnosis and personalized treatment. Streamlined sample preparation and compact platforms such as the SmidgION enhance their versatility, even in challenging environments, creating significant market opportunities for portable genome sequencing solutions.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The global genome sequencing market has been segmented based on various categories, such as by product, technology, type, application, end user, and region.

Growth/Marketing Strategy: Partnerships, alliances, funding, new offerings, and business expansions together accounted for the maximum number of key developments of the total developments in the genome sequencing market between January 2021 and April 2024.

Competitive Strategy: The global genome sequencing market is a highly fragmented market, with many public and few private companies. Key players in the genome sequencing market analyzed and profiled in the study involve established players that offer various kinds of products.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2019-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of genome sequencing.
• The market contribution of genome sequencing anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
• Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023.
• The market has been mapped based on the available genome sequencing products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in genome sequencing, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Validation of the numbers of the different segments of the market in focus
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others.
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• Segmentations and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• 10X Genomics, Inc.
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Eurofins Scientific S.E.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• OncoDNA
• MGI Tech Co., Ltd.
• MicroGen Diagnostics
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Phase Genomics, Inc.
• QIAGEN N.V.
• Revvity, Inc.
• Singular Genomics Systems, Inc.
• Thermo Fisher Scientific Inc.
• Ultima Genomics, Inc.
• Element Biosciences, Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Global Genome Sequencing Market: Industry Analysis

• 1.1 Key Trends: Current and Future Impact Assessment
  • 1.1.1 Integration of Artificial Intelligence and Machine Learning in Genome Sequencing
  • 1.1.2 Increasing Partnerships, Alliances, and Business Expansions among Key Players
• 1.2 Regulatory Analysis
• 1.3 Value and Supply Chain Analysis

2 Global Genome Sequencing Market: Market Dynamics

• 2.1 Impact Analysis
• 2.2 Market Drivers
  • 2.2.1 Decreasing Cost of Genome Sequencing Enabling High Usage of Genome Sequencing/Testing
  • 2.2.2 Rising Prenatal and New-Born Screening Programs Facilitating the Demand for Next-Generation Sequencing
  • 2.2.3 Expanding Applications of Long-Read Sequencing
  • 2.2.4 Government Investments and Initiatives in Genome Sequencing Projects
• 2.3 Market Restraints
  • 2.3.1 Data Management Challenges in Genome Sequencing
  • 2.3.2 Genomic Data Disparity in Developing Countries
• 2.4 Market Opportunities
  • 2.4.1 Emergence of Portable Genome Sequencing Enabling Bedside Testing
  • 2.4.2 Multiomics Shaping the Global Genome Sequencing Landscape

3 Global Genome Sequencing Market: Future Outlook

• 3.1 Patent Analysis
  • 3.1.1 Patent Analysis (by Year)
  • 3.1.2 Patent Analysis (by Country)
• 3.2 Competitive Benchmarking
  • 3.2.1 Market Share
  • 3.2.2 Brand Recognition
• 3.3 Sequencing Clinical Adoption
• 3.4 Future Outlook

4 Global Genome Sequencing Market (by Product)

• 4.1 Product Summary
• 4.2 Kits
  • 4.2.1 Genomic Sample Isolation Kits
  • 4.2.2 Library Preparation Kits
  • 4.2.3 Sequencing Kits
• 4.3 Instruments
  • 4.3.1 Sample Isolation Instruments
    • 4.3.1.1 Automated
    • 4.3.1.2 Semi-Automated
  • 4.3.2 Sequencers
    • 4.3.2.1 Low-Throughput Sequencers
    • 4.3.2.2 High-Throughput Sequencers
    • 4.3.2.3 Ultra-High-Throughput Sequencers
  • 4.3.3 Other Instruments
• 4.4 Software
  • 4.4.1 Data Analytics/Bioinformatics
  • 4.4.2 Reporting

5 Global Genome Sequencing Market (by Technology)

• 5.1 Technology Summary
• 5.2 By Competitive Analysis
• 5.3 First-Generation Sequencing
• 5.4 Next-Generation Sequencing
  • 5.4.1 Sequencing by Synthesis
  • 5.4.2 Sequencing by Ligation
• 5.5 Third-Generation Sequencing
  • 5.5.1 Single-Molecule Real-Time Sequencing
  • 5.5.2 Nanopore Sequencing
  • 5.5.3 Electron Microscopy
• 5.6 Fourth-Generation Sequencing

6 Global Genome Sequencing Market (by Type)

• 6.1 Type Summary
• 6.2 Whole Genome Sequencing
• 6.3 Whole Exome Sequencing
• 6.4 Targeted Sequencing
• 6.5 RNA Sequencing

7 Global Genome Sequencing Market (by Application)

• 7.1 Application Summary
• 7.2 Research
  • 7.2.1 Basic and Translational Research
    • 7.2.1.1 Oncology
    • 7.2.1.2 Non-Oncology
  • 7.2.2 Population Genomics Studies
  • 7.2.3 Epidemiology Research
  • 7.2.4 Others
• 7.3 Clinical Diagnostics
  • 7.3.1 Liquid Biopsy
  • 7.3.2 Companion Diagnostics
  • 7.3.3 NIPT
  • 7.3.4 Pharmacogenomics
  • 7.3.5 MRD Testing
  • 7.3.6 Genetic Testing
  • 7.3.7 Others
• 7.4 Biopharma R&D
  • 7.4.1 Drug Discovery
  • 7.4.2 Clinical Trials and Development
• 7.5 Food and Agriculture
• 7.6 Forensics

8 Global Genome Sequencing Market (by End User)

• 8.1 End User Summary
• 8.2 Pharmaceutical and Biotechnology Companies
• 8.3 Hospitals and Diagnostic Laboratories
• 8.4 Population Sequencing Organizations
• 8.5 Research and Academic Institutes
• 8.6 Others

9 Global Genome Sequencing Market (By Region)

• 9.1 Regional Summary
• 9.2 Drivers and Restraints
• 9.3 North America
  • 9.3.1 Regional Overview
  • 9.3.2 Driving Factors for Market Growth
  • 9.3.3 Factors Challenging the Market
  • 9.3.4 By Product
  • 9.3.5 By End User
  • 9.3.6 U.S.
    • 9.3.6.1 By Product
  • 9.3.7 Canada
    • 9.3.7.1 By Product
• 9.4 Europe
  • 9.4.1 Regional Overview
  • 9.4.2 Driving Factors for Market Growth
  • 9.4.3 Factors Challenging the Market
  • 9.4.4 By Product
  • 9.4.5 By End User
  • 9.4.6 Germany
    • 9.4.6.1 By Product
  • 9.4.7 U.K.
    • 9.4.7.1 By Product
  • 9.4.8 Spain
    • 9.4.8.1 By Product
  • 9.4.9 Italy
    • 9.4.9.1 By Product
  • 9.4.10 France
    • 9.4.10.1 By Product
  • 9.4.11 Rest-of-Europe
    • 9.4.11.1 By Product
• 9.5 Asia-Pacific
  • 9.5.1 Regional Overview
  • 9.5.2 Driving Factors for Market Growth
  • 9.5.3 Factors Challenging the Market
  • 9.5.4 By Product
  • 9.5.5 By End User
  • 9.5.6 China
    • 9.5.6.1 By Product
  • 9.5.7 Japan
    • 9.5.7.1 By Product
  • 9.5.8 India
    • 9.5.8.1 By Product
  • 9.5.9 Australia
    • 9.5.9.1 By Product
  • 9.5.10 South Korea
    • 9.5.10.1 By Product
  • 9.5.11 Rest-of-Asia-Pacific
    • 9.5.11.1 By Product
• 9.6 Latin America
  • 9.6.1 Regional Overview
  • 9.6.2 Driving Factors for Market Growth
  • 9.6.3 Factors Challenging the Market
  • 9.6.4 Brazil
    • 9.6.4.1 By Product
  • 9.6.5 Mexico
    • 9.6.5.1 By Product
  • 9.6.6 Rest-of-Latin America
    • 9.6.6.1 By Product
• 9.7 Rest-of-the-World
  • 9.7.1 Regional Overview
  • 9.7.2 Driving Factors for Market Growth
  • 9.7.3 Factors Challenging the Market
  • 9.7.4 By Product
  • 9.7.5 By End User

10 Global Genome Sequencing Market - Competitive Benchmarking and Company Profiles

• 10.1 Key Strategies and Development
  • 10.1.1 Partnerships, Alliances, and Business Expansions
  • 10.1.2 Regulatory and Legal Activities
  • 10.1.3 New Offerings
  • 10.1.4 Mergers and Acquisitions
  • 10.1.5 Funding Activities
• 10.2 Company Profiles
  • 10.2.1 10X Genomics, Inc.
    • 10.2.1.1 Overview
    • 10.2.1.2 Top Products and Services
    • 10.2.1.3 Top Competitors
    • 10.2.1.4 Key Personnel
    • 10.2.1.5 Analyst View
  • 10.2.2 Agilent Technologies, Inc.
    • 10.2.2.1 Overview
    • 10.2.2.2 Top Products and Services
    • 10.2.2.3 Top Competitors
    • 10.2.2.4 Key Personnel
    • 10.2.2.5 Analyst View
  • 10.2.3 Becton, Dickinson and Company
    • 10.2.3.1 Overview
    • 10.2.3.2 Top Products and Services
    • 10.2.3.3 Top Competitors
    • 10.2.3.4 Key Personnel
    • 10.2.3.5 Analyst View
  • 10.2.4 Eurofins Scientific S.E.
    • 10.2.4.1 Overview
    • 10.2.4.2 Top Products and Services
    • 10.2.4.3 Top Competitors
    • 10.2.4.4 Key Personnel
    • 10.2.4.5 Analyst View
  • 10.2.5 F. Hoffmann-La Roche Ltd.
    • 10.2.5.1 Overview
    • 10.2.5.2 Top Products and Services
    • 10.2.5.3 Top Competitors
    • 10.2.5.4 Key Personnel
    • 10.2.5.5 Analyst View
  • 10.2.6 Illumina, Inc.
    • 10.2.6.1 Overview
    • 10.2.6.2 Top Products and Services
    • 10.2.6.3 Top Competitors
    • 10.2.6.4 Key Personnel
    • 10.2.6.5 Analyst View
  • 10.2.7 OncoDNA
    • 10.2.7.1 Overview
    • 10.2.7.2 Top Products and Services
    • 10.2.7.3 Top Competitors
    • 10.2.7.4 Key Personnel
    • 10.2.7.5 Analyst View
  • 10.2.8 MGI Tech Co., Ltd.
    • 10.2.8.1 Overview
    • 10.2.8.2 Top Products and Services
    • 10.2.8.3 Top Competitors
    • 10.2.8.4 Key Personnel
    • 10.2.8.5 Analyst View
  • 10.2.9 MicroGen Diagnostics
    • 10.2.9.1 Overview
    • 10.2.9.2 Top Products and Services
    • 10.2.9.3 Top Competitors
    • 10.2.9.4 Key Personnel
    • 10.2.9.5 Analyst View
  • 10.2.10 Oxford Nanopore Technologies plc
    • 10.2.10.1 Overview
    • 10.2.10.2 Top Products and Services
    • 10.2.10.3 Top Competitors
    • 10.2.10.4 Key Personnel
    • 10.2.10.5 Analyst View
  • 10.2.11 Pacific Biosciences of California, Inc.
    • 10.2.11.1 Overview
    • 10.2.11.2 Top Products and Services
    • 10.2.11.3 Top Competitors
    • 10.2.11.4 Key Personnel
    • 10.2.11.5 Analyst View
  • 10.2.12 Phase Genomics, Inc.
    • 10.2.12.1 Overview
    • 10.2.12.2 Top Products and Services
    • 10.2.12.3 Top Competitors
    • 10.2.12.4 Key Personnel
    • 10.2.12.5 Analyst View
  • 10.2.13 QIAGEN N.V.
    • 10.2.13.1 Overview
    • 10.2.13.2 Top Products and Services
    • 10.2.13.3 Top Competitors
    • 10.2.13.4 Key Personnel
    • 10.2.13.5 Analyst View
  • 10.2.14 Revvity, Inc.
    • 10.2.14.1 Overview
    • 10.2.14.2 Top Products and Services
    • 10.2.14.3 Top Competitors
    • 10.2.14.4 Key Personnel
    • 10.2.14.5 Analyst View
  • 10.2.15 Singular Genomics Systems, Inc.
    • 10.2.15.1 Overview
    • 10.2.15.2 Top Products and Services
    • 10.2.15.3 Top Competitors
    • 10.2.15.4 Key Personnel
    • 10.2.15.5 Analyst View
  • 10.2.16 Thermo Fisher Scientific Inc.
    • 10.2.16.1 Overview
    • 10.2.16.2 Top Products and Services
    • 10.2.16.3 Top Competitors
    • 10.2.16.4 Key Personnel
    • 10.2.16.5 Analyst View
  • 10.2.17 Ultima Genomics, Inc.
    • 10.2.17.1 Overview
    • 10.2.17.2 Top Products and Services
    • 10.2.17.3 Top Competitors
    • 10.2.17.4 Key Personnel
    • 10.2.17.5 Analyst View
  • 10.2.18 Element Biosciences, Inc.
    • 10.2.18.1 Overview
    • 10.2.18.2 Top Products and Services
    • 10.2.18.3 Top Competitors
    • 10.2.18.4 Key Personnel
    • 10.2.18.5 Analyst View

11 Research Methodology

• 11.1 Data Sources
  • 11.1.1 Primary Data Sources
  • 11.1.2 Secondary Data Sources
  • 11.1.3 Data Triangulation